Characterization of the role of IL-6 in the progression of prostate cancer
- PMID: 10068344
- DOI: 10.1002/(sici)1097-0045(19990215)38:3<199::aid-pros4>3.0.co;2-h
Characterization of the role of IL-6 in the progression of prostate cancer
Abstract
Background: We recently identified IL-6, a pleiotropic cytokine implicated in the neoplastic process of a variety of neoplasms, as a mediator of prostate cancer morbidity. In the present study, we investigated the expression of members of the IL-6 supergene family and related cytokines and the potential role of IL-6 in prostate cancer growth regulation.
Methods: Five established human prostate cancer cell lines were screened by ELISA for production of granulocyte colony-stimulating factor (G-CSF), leukemia inhibitory factor (LIF), ciliary neurotrophic factor (CNTF), oncostatin M (OSM), tumor necrosis factor (TNF), interleukin-1 (IL-1), and granulocyte macrophage colony-stimulating factor (GM-CSF). Expression of the ligand-binding component of the IL-6 receptor, IL-6Rp80, was evaluated by ELISA and RT-PCR. Sequential immunoprecipitation and immunoblotting were performed to assay for expression of the signal-transducing component of the IL-6 receptor, gp130. The effects of IL-6 on cell growth were assessed by MTT assays.
Results: The three hormone-refractory cell lines, DU-145, TSU, and PC-3, secreted distinct combinations of cytokines (DU-145: IL-6, GM-CSF; TSU: IL-6, LIF; PC-3: IL-6, G-CSF, LIF, IL-1, GM-CSF), each uniformly expressing IL-6. In contrast, neither of the two hormone-dependent cell lines, LNCaP-ATCC and LNCaP-GW, secreted significant quantities of any of the cytokines analyzed. None of the cell lines secreted detectable quantities of OSM, CNTF, or TNF. All cell lines, irrespective of hormone status, expressed both Il-6Rp80 and gp130. Addition of IL-6 in vitro inhibited growth of hormone-dependent cells, but had no effect on hormone-refractory lines. Anti-IL-6 neutralizing antibody inhibited growth of hormone-refractory cells.
Conclusions: IL-6 appears to undergo a functional transition from paracrine growth inhibitor to autocrine growth stimulator during progression of prostate cancer to the hormone-refractory phenotype.
Similar articles
-
Direct synergistic effects of leukemia inhibitory factor on hematopoietic progenitor cell growth: comparison with other hematopoietins that use the gp130 receptor subunit.Blood. 1996 Aug 1;88(3):863-9. Blood. 1996. PMID: 8704242
-
Ciliary neurotropic factor, interleukin 11, leukemia inhibitory factor, and oncostatin M are growth factors for human myeloma cell lines using the interleukin 6 signal transducer gp130.J Exp Med. 1994 Apr 1;179(4):1337-42. doi: 10.1084/jem.179.4.1337. J Exp Med. 1994. PMID: 8145045 Free PMC article.
-
Immunohistochemical analysis of the IL-6 family of cytokines and their receptors in benign, hyperplasic, and malignant human prostate.J Pathol. 2004 Jan;202(1):41-9. doi: 10.1002/path.1476. J Pathol. 2004. PMID: 14694520
-
The emerging neuropoietic cytokine family: first CDF/LIF, CNTF and IL-6; next ONC, MGF, GCSF?Curr Opin Neurobiol. 1992 Feb;2(1):94-7. doi: 10.1016/0959-4388(92)90169-l. Curr Opin Neurobiol. 1992. PMID: 1386269 Review.
-
Interleukin-6 Family of Cytokines in Cancers.J Interferon Cytokine Res. 2024 Feb;44(2):45-59. doi: 10.1089/jir.2023.0103. Epub 2024 Jan 17. J Interferon Cytokine Res. 2024. PMID: 38232478 Review.
Cited by
-
Magmas expression in neoplastic human prostate.J Mol Histol. 2005 Feb;36(1-2):69-75. doi: 10.1007/s10735-004-3840-8. J Mol Histol. 2005. PMID: 15704001
-
What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 4: Experimental Treatments in Pre-Clinical Studies (Cell Lines and Mouse Models).Int J Mol Sci. 2021 Nov 14;22(22):12297. doi: 10.3390/ijms222212297. Int J Mol Sci. 2021. PMID: 34830179 Free PMC article.
-
The picture of the prostatic lymphokine network is becoming increasingly complex.Rev Urol. 2002 Fall;4(4):171-7. Rev Urol. 2002. PMID: 16985676 Free PMC article.
-
Phenethyl isothiocyanate inhibits STAT3 activation in prostate cancer cells.Mol Nutr Food Res. 2009 Jul;53(7):878-86. doi: 10.1002/mnfr.200800253. Mol Nutr Food Res. 2009. PMID: 19437484 Free PMC article.
-
Dissecting Major Signaling Pathways throughout the Development of Prostate Cancer.Prostate Cancer. 2013;2013:920612. doi: 10.1155/2013/920612. Epub 2013 Apr 29. Prostate Cancer. 2013. PMID: 23738079 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical